Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 09 - 09 save search
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
Published: 2021-09-09 (Crawled : 21:00) - globenewswire.com
ATAI | $1.97 5.35% 5.08% 1.2M
|
Manufacturing
|
| O: 1.06%
H: 0.0%
C: -4.02%
treatment test depression life science ketamine
Water Treatment Chemicals Market Size to Reach Revenues of USD 38,119.46 Million by 2026 - Arizton
Published: 2021-09-09 (Crawled : 20:00) - prnewswire.com
ITT | $129.54 3.01% 0.0% 350K
|
Producer Manufacturing
|
| O: 0.52%
H: 0.12%
C: -0.98%
EMN | $96.8 -0.27% 0.0% 520K
|
Process Industries
|
| O: 0.71%
H: 1.07%
C: -0.62%
CBT | News | $93.38 0.71% 0.0% 160K
|
Process Industries
|
| O: 0.89%
H: 0.0%
C: -3.27%
treatment
Marrone Bio Prepares to Submit Registration for Next-Generation Crop Protection Product in North AmericaCompany Also Looks to Expand Footprint in South America with Regulatory Submission of Bionematicide Seed Treatment, MBI-206, in Brazil
Published: 2021-09-09 (Crawled : 19:00) - biospace.com/
MBII | $0.7981 -20.19% 1.49%
|
Process Industries
|
| O: 2.27%
H: 0.78%
C: -5.07%
treatment brazil submission drop
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher DiseaseClinical trial site initiation for Gaucher disease Type 1 on track by year end
Published: 2021-09-09 (Crawled : 15:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: -0.25%
disease treatment orphan drug drug trial pons designation
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS— Investigational EIF2B activator approach has potential to be a first-in-class treatment for ALS —
Published: 2021-09-09 (Crawled : 14:00) - biospace.com/
DNLI | $16.11 0.75% 0.74% 1.1M
|
Health Technology
|
| O: -0.11%
H: 2.54%
C: -0.3%
treatment phase 1 potential phase 1b als phase 2b
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
Published: 2021-09-09 (Crawled : 13:00) - biospace.com/
DBTX | $4.91 -0.81% -0.2% 0
|
Health Technology
|
| O: 4.66%
H: 3.72%
C: -2.85%
disease treatment rare pediatric disease designation orphan drug drug hearing loss designation rare
Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations
Published: 2021-09-09 (Crawled : 12:00) - globenewswire.com
ELOX | $0.8025 -51.57% 93K
|
Health Technology
|
| O: 5.76%
H: 14.29%
C: 4.08%
treatment fibrosis fast track fast track designation elx-02 designation cystic fibrosis
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $39.61 3.34% 0.0% 2.1M
|
Health Technology
|
| O: -0.14%
H: 2.85%
C: -0.58%
treatment europe migraine therapy
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
Published: 2021-09-09 (Crawled : 12:00) - biospace.com/
SNGX | $0.4012 -1.13% -1.15% 450K
|
Health Technology
|
| O: 12.38%
H: 4.24%
C: -1.69%
treatment fda drug t-cell granted grant designation
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
Published: 2021-09-09 (Crawled : 08:00) - globenewswire.com
RARE F | $45.06 3.14% 3.04% 840K
|
Health Technology
|
| O: -0.58%
H: 2.56%
C: -0.46%
media treatment approval
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Published: 2021-09-09 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.54%
H: 0.23%
C: -0.59%
treatment phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.